Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab

Qichen Hu, Yijing Zhao, Siqi Zhang, Kun Wang, Xin Gao, Dengfu Wu, Jieting Shen, Qingshuang Lu, Xuekai Song, Quan Zuo, Robert Gale, Rui Wang, Xiaojun Huang, Kuan Hu

Blood (2025) 146 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2025-5052

Published: 2025

Journal Articles

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

Michael Wallington, Yong Chen, Fei Jie, Monica Patterson, Karen Repetny, Michelle Fanale, Simon Purcell, Jacob Ambrose, Christina Zettler, Andrew Belli, Laura L. Fernandes, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2025-4511

Published: 2025

Journal Articles

Macrophage subsets provide distinct niches for normal and clonal hematopoiesis

Yirong Zhang, Zixuan Xu, Kun Wang, Dachuan Zhang

Blood (2025) 146 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2025-1402

Published: 2025

Journal Articles

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli, Eric Hansen, Christina Zettler, Laura Fernandes, Ming He, Stephanie Wiley, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 4606.

https://doi.org/10.1182/blood-2025-4606

Published: 2025

Journal Articles

R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL

Danielle Wallace, Claire Bai, Andrew Belli, Eric Hansen, Christina Zettler, Laura Fernandes, Stephanie Wiley, Ching-Kun Wang, Paul Barr

Blood (2025) 146 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2025-6277

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli, Eric Hansen, Christina Zettler, Laura Fernandes, Stephanie Wiley, Courtney Anderson, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 601.

https://doi.org/10.1182/blood-2025-601

Published: 2025

Journal Articles

Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with Mantle Cell Lymphoma By LOT

Helmneh M. Sineshaw, Claire Bai, Enrico De Nigris, Jennifer Prescott, Uzor C. Ogbu, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang

Blood (2024) 144 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2024-194230

Published: 2024

Journal Articles

Transcriptional Regulation of Cytotoxic T-Cell Responses in Acute Myeloid Leukemia

Xufeng Chen, Zhengxi Sun, Jana Elegast, Hua Zhou, Soobeom Lee, Deedra Nicolet, Qiao Lu, Kun Wang, Jun Wang, Wafa Al-Santli, Ann-Kathrin Eisfeld, Kimberly Stegmaier, Iannis Aifantis, Rebecca Austin

Blood (2024) 144 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2024-193591

Published: 2024

Journal Articles

Improved Outcomes with Bu/Cy+Melphalan and Bu/Cy+Thiotepa Regimens in Haploidentical Hematopoietic Stem Cell Transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia

Zhijie Wei, Fei Pan, Jing Long, Guanlan Yue, Kang Gao, Kun Wang, Huili Zhu, Yujie Wang, Zheren Wang, Peihua Lu

Blood (2024) 144 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2024-206814

Published: 2024

Journal Articles

End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting

Paul A. Hamlin, Pallawi Torka, Eric Hansen, Andrew J. Belli, Jacob Ambrose, Christina M. Zettler, Laura L. Fernandes, Stephanie Wiley, Brittney Perry, Ching-Kun Wang

Blood (2024) 144 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2024-203786

Published: 2024

Journal Articles

Prophylactic Basiliximab on Days +1 and +4 Post-Haploidentical Hematopoietic Stem Cell Transplantation Reduces Incidence of Grade II-IV Acute Graft-Versus-Host Disease in Acute Myeloid Leukemia Patients in Complete Remission (M1, M2, and M4 Subtypes)

Zhijie Wei, Fei Pan, Jing Long, Zheren Wang, Guanlan Yue, Kang Gao, Kun Wang, Huili Zhu, Yujie Wang, Peihua Lu

Blood (2024) 144 (Supplement 1): 7363.

https://doi.org/10.1182/blood-2024-206773

Published: 2024

Journal Articles

Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Paul A. Hamlin, Pallawi Torka, Eric Hansen, Andrew J. Belli, Jacob Ambrose, Christina M. Zettler, Laura L. Fernandes, Stephanie Wiley, Brittney Perry, Ching-Kun Wang

Blood (2024) 144 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2024-208852

Published: 2024

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Muhammad Saad Hamid, Claire Bai, Chelsea Perelgut, Helena Yelovich, Christina M. Zettler, Laura L. Fernandes, Andrew J. Belli, Eric Hansen, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2023-182064

Published: 2023

Journal Articles

Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Using Busulfan/Cyclophosphamide and Melphalan or Thiotepa As Conditioning Regimen in 37 Patients with Acute Megakaryoblastic Leukemia

Fei Pan, Hongxing Liu, Sr., Guanlan Yue, Kang Gao, Kun Wang, Huili Zhu, Yujie Wang, Zheren Wang, Zhijie Wei

Blood (2023) 142 (Supplement 1): 6964.

https://doi.org/10.1182/blood-2023-181494

Published: 2023

Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Blood (2023) 142 (Supplement 1): 6538.

https://doi.org/10.1182/blood-2023-180060

Published: 2023

Journal Articles

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Rebecca Bystrom, Laura L. Fernandes, Joseph Wynne, Dianne Pulte, Eric Hansen, Andrew J. Belli, Anna Barcellos, Christina M. Zettler, Jonathon Vallejo, Kelly Norsworthy, Angelo De Claro, Catherine Lerro, Marc R Theoret, Ching-Kun Wang, Donna Rivera

Blood (2023) 142 (Supplement 1): 5189.

https://doi.org/10.1182/blood-2023-189060

Published: 2023

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Vishal Bhatnagar, Bindu Kanapuru, Laura Fernandes, Ting-Yu Chen, Mallorie H. Fiero, Erica Horodniceanu, Nicole Gormley, Catherine Lerro, Fatima Rizvi, Yuan-Li Shen, Felice Yang, Anna Barcellos, Andrew J. Belli, Eric Hansen, Ching-Kun Wang, Donna Rivera, Paul Kluetz

Blood (2022) 140 (Supplement 1): 7156–7157.

https://doi.org/10.1182/blood-2022-166842

Published: 2022

Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4142–4143.

https://doi.org/10.1182/blood-2022-170596

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

Macrophage subsets provide distinct niches for normal and clonal hematopoiesis

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with Mantle Cell Lymphoma By LOT

Transcriptional Regulation of Cytotoxic T-Cell Responses in Acute Myeloid Leukemia

Improved Outcomes with Bu/Cy+Melphalan and Bu/Cy+Thiotepa Regimens in Haploidentical Hematopoietic Stem Cell Transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia

End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting

Prophylactic Basiliximab on Days +1 and +4 Post-Haploidentical Hematopoietic Stem Cell Transplantation Reduces Incidence of Grade II-IV Acute Graft-Versus-Host Disease in Acute Myeloid Leukemia Patients in Complete Remission (M1, M2, and M4 Subtypes)

Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Using Busulfan/Cyclophosphamide and Melphalan or Thiotepa As Conditioning Regimen in 37 Patients with Acute Megakaryoblastic Leukemia

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only